<!DOCTYPE html><html lang="zh-CN"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1"><title>药捷安康-B | 严振杰</title><link rel="shortcut icon" href="/images/my_logo.svg"><meta name="keywords" content="严振杰,严振杰投资"><meta name="description" content="他说正直刚烈嫉恶如仇且有勇有谋文武双全！"><meta name="author" content="严振杰"><script src="https://cdn.tailwindcss.com/3.3.3"></script><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.7.2/css/all.min.css"><script src="https://cdnjs.cloudflare.com/ajax/libs/Chart.js/3.9.1/chart.min.js"></script><style>body{font-family:'Noto Sans SC',sans-serif;background:linear-gradient(135deg,#f5f7fa 0,#e4edf5 100%);color:#2d3748;overflow-x:hidden}.glassmorphism{background:rgba(255,255,255,.7);backdrop-filter:blur(10px);border-radius:16px;border:1px solid rgba(255,255,255,.3);box-shadow:0 8px 32px 0 rgba(31,38,135,.15)}.card-hover{transition:all .3s ease}.card-hover:hover{transform:translateY(-5px);box-shadow:0 12px 28px 0 rgba(31,38,135,.2)}.chart-container{height:320px;width:100%;position:relative}.highlight-text{position:relative;display:inline-block}.highlight-text::after{content:'';position:absolute;bottom:0;left:0;width:100%;height:10px;background-color:rgba(99,102,241,.2);z-index:-1}.data-pill{display:inline-block;padding:2px 12px;border-radius:16px;font-size:14px;font-weight:500;background:rgba(99,102,241,.1);color:#4f46e5;margin-right:8px;margin-bottom:8px}.bg-gradient-primary{background:linear-gradient(135deg,#4f46e5 0,#7c3aed 100%)}.shadow-glow{box-shadow:0 10px 25px -5px rgba(99,102,241,.5)}.up-color{color:#ef4444}.down-color{color:#10b981}.mobile-menu{position:absolute;top:100%;left:0;right:0;padding:1rem;margin:.5rem;border-radius:.75rem;background:rgba(255,255,255,.9);backdrop-filter:blur(10px);border:1px solid rgba(255,255,255,.3);box-shadow:0 8px 32px 0 rgba(31,38,135,.15);transform-origin:top;transform:scaleY(0);opacity:0;transition:transform .3s ease,opacity .3s ease;z-index:100}.mobile-menu.active{transform:scaleY(1);opacity:1}.mobile-menu a{display:block;padding:.75rem 1rem;border-radius:.5rem;margin-bottom:.5rem;font-weight:500;transition:all .2s ease}.mobile-menu a:focus,.mobile-menu a:hover{background-color:rgba(99,102,241,.1);color:#4f46e5}</style></head><body class="min-h-screen"><nav class="glassmorphism sticky top-0 z-50 p-4 mb-8" id="mainNav"><div class="container mx-auto flex items-center justify-between"><div class="text-xl font-bold bg-gradient-to-r from-indigo-600 to-purple-600 text-transparent bg-clip-text"><i class="fas fa-chart-line mr-2"></i>药捷安康股价前瞻报告</div><div class="hidden md:flex space-x-6"><a href="#summary" class="text-gray-600 hover:text-indigo-600 transition-colors">执行摘要</a> <a href="#products" class="text-gray-600 hover:text-indigo-600 transition-colors">核心产品</a> <a href="#technical" class="text-gray-600 hover:text-indigo-600 transition-colors">技术面分析</a> <a href="#forecast" class="text-gray-600 hover:text-indigo-600 transition-colors">股价预测</a> <a href="#risks" class="text-gray-600 hover:text-indigo-600 transition-colors">风险提示</a></div><button class="md:hidden text-gray-600 focus:outline-none" id="mobileMenuButton" aria-label="导航菜单"><i class="fas fa-bars"></i></button><div class="mobile-menu md:hidden" id="mobileMenu"><a href="#summary" class="text-gray-600 hover:text-indigo-600 transition-colors flex items-center"><i class="fas fa-file-alt mr-3 text-indigo-500"></i>执行摘要 </a><a href="#products" class="text-gray-600 hover:text-indigo-600 transition-colors flex items-center"><i class="fas fa-pills mr-3 text-indigo-500"></i>核心产品 </a><a href="#technical" class="text-gray-600 hover:text-indigo-600 transition-colors flex items-center"><i class="fas fa-chart-bar mr-3 text-indigo-500"></i>技术面分析 </a><a href="#forecast" class="text-gray-600 hover:text-indigo-600 transition-colors flex items-center"><i class="fas fa-bullseye mr-3 text-indigo-500"></i>股价预测 </a><a href="#risks" class="text-gray-600 hover:text-indigo-600 transition-colors flex items-center"><i class="fas fa-exclamation-triangle mr-3 text-indigo-500"></i>风险提示</a></div></div></nav><header class="container mx-auto py-16 px-4 md:px-8 relative"><div class="max-w-4xl mx-auto text-center"><h1 class="text-4xl md:text-5xl font-bold mb-6">药捷安康（02617.HK）股价前瞻报告</h1><p class="text-xl md:text-2xl text-gray-600 mb-8">小分子创新疗法临床阶段生物制药公司</p><div class="flex flex-wrap justify-center gap-4"><div class="stat-card glassmorphism p-4 text-center w-40"><div class="text-sm text-gray-500">当前股价</div><div class="text-2xl font-bold text-indigo-600">192.5港元</div></div><div class="stat-card glassmorphism p-4 text-center w-40"><div class="text-sm text-gray-500">短期目标价</div><div class="text-2xl font-bold up-color">220-250港元</div></div><div class="stat-card glassmorphism p-4 text-center w-40"><div class="text-sm text-gray-500">中期目标价</div><div class="text-2xl font-bold up-color">350-400港元</div></div><div class="stat-card glassmorphism p-4 text-center w-40"><div class="text-sm text-gray-500">长期目标价</div><div class="text-2xl font-bold up-color">400-500港元</div></div></div></div></header><section id="summary" class="container mx-auto py-12 px-4 md:px-8"><div class="glassmorphism p-8 mb-16"><h2 class="text-3xl font-bold mb-6 flex items-center"><div class="w-10 h-10 rounded-full bg-gradient-primary flex items-center justify-center text-white mr-3"><i class="fas fa-file-alt"></i></div>执行摘要</h2><div class="grid grid-cols-1 md:grid-cols-2 gap-8"><div><p class="mb-4">药捷安康（02617.HK）作为专注于小分子创新疗法的临床阶段生物制药公司，当前股价（截至2025年9月12日）为<span class="highlight-text">192.5港元</span>，对应市值764.03亿港元。基于核心产品替恩戈替尼（TT-00420）的临床进展与技术面信号，我们预测其短中长期目标价分别为<span class="highlight-text">220-250港元</span>、<span class="highlight-text">350-400港元/150-180港元</span>及<span class="highlight-text">400-500港元</span>，股价驱动逻辑呈现"临床里程碑突破+技术面趋势强化"的双重特征。</p><div class="my-6"><h4 class="font-semibold text-lg mb-3 text-gray-700">核心产品：全球稀缺性与临床进展共振</h4><p class="mb-4">替恩戈替尼作为<span class="highlight-text">全球首个FGFR/JAK多靶点激酶抑制剂</span>，其差异化机制在胆管癌、乳腺癌等适应症中展现显著潜力。该产品针对FGFR抑制剂耐药的胆管癌转化医学结果已发表于《肿瘤学年鉴》（影响因子56.7），并获美国FDA授予转移性去势抵抗性前列腺癌（mCRPC）快速通道认证，凸显全球竞争力。</p></div><div class="my-6"><h4 class="font-semibold text-lg mb-3 text-gray-700">近期临床进展</h4><div class="flex flex-wrap"><div class="data-pill"><i class="fas fa-flask mr-1"></i> 乳腺癌II期临床获批</div><div class="data-pill"><i class="fas fa-user-md mr-1"></i> 肝癌II期首例给药</div><div class="data-pill"><i class="fas fa-trophy mr-1"></i> FDA快速通道认证</div><div class="data-pill"><i class="fas fa-vial mr-1"></i> 胆管癌III期进行中</div></div></div></div><div><div class="chart-container"><canvas id="summaryChart"></canvas></div><div class="mt-6 bg-blue-50 rounded-xl p-4"><h4 class="font-semibold text-lg mb-2 text-blue-800">短中长期预测与核心风险</h4><p class="text-gray-700 mb-2"><span class="font-semibold">短期（6个月内）</span>：乳腺癌II期临床启动、肝癌II期患者入组数据有望持续催化股价，目标价220-250港元</p><p class="text-gray-700 mb-2"><span class="font-semibold">中期（12-24个月）</span>：胆管癌III期临床结果为关键节点，成功则目标价350-400港元，失败或显著低于150-180港元</p><p class="text-gray-700"><span class="font-semibold">长期（3-5年）</span>：若替恩戈替尼获批上市，凭借多适应症布局有望成为全球重磅产品，目标价400-500港元</p></div></div></div></div></section><section id="products" class="container mx-auto py-12 px-4 md:px-8"><h2 class="text-3xl font-bold mb-12 text-center">公司核心产品分析</h2><div class="grid grid-cols-1 lg:grid-cols-3 gap-8 mb-16"><div class="glassmorphism p-8 card-hover col-span-1 lg:col-span-3"><div class="flex items-center mb-4"><div class="w-12 h-12 rounded-full bg-gradient-primary flex items-center justify-center text-white mr-4 shadow-glow"><i class="fas fa-pills"></i></div><h3 class="text-2xl font-semibold">核心产品替恩戈替尼</h3></div><p class="text-gray-600 mb-6">替恩戈替尼（Tinengotinib, TT-00420）作为药捷安康的核心候选药物，是一种全球首创的多靶点激酶抑制剂（MTK），通过差异化分子设计实现FGFR/VEGFR、JAK及Aurora激酶通路的协同抑制，其独特作用机制为解决实体瘤耐药难题提供了全新解决方案。</p><div class="grid grid-cols-1 md:grid-cols-3 gap-6"><div class="bg-gradient-to-r from-blue-50 to-indigo-50 rounded-xl p-4"><div class="text-indigo-600 text-xl mb-2"><i class="fas fa-dna mr-2"></i>多靶点协同机制</div><p class="text-sm text-gray-600">FGFR通路抑制直接阻断肿瘤细胞增殖信号，JAK通路阻断则通过抑制STAT3等下游分子减少免疫抑制性细胞因子释放，从而逆转肿瘤微环境的免疫逃逸</p></div><div class="bg-gradient-to-r from-purple-50 to-pink-50 rounded-xl p-4"><div class="text-purple-600 text-xl mb-2"><i class="fas fa-chart-line mr-2"></i>临床数据验证</div><p class="text-sm text-gray-600">在43例既往FGFR抑制剂治疗进展的晚期胆道癌患者中，替恩戈替尼单药治疗的客观缓解率（ORR）达30%，疾病控制率（DCR）高达93%</p></div><div class="bg-gradient-to-r from-green-50 to-teal-50 rounded-xl p-4"><div class="text-green-600 text-xl mb-2"><i class="fas fa-award mr-2"></i>监管资质</div><p class="text-sm text-gray-600">NMPA授予胆管癌适应症"突破性治疗品种"认定，FDA授予胆管癌及mCRPC两项"快速通道资格"，EMA授予胆道癌"孤儿药认定"</p></div></div></div></div><div class="grid grid-cols-1 md:grid-cols-2 gap-8 mb-16"><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-indigo-100 flex items-center justify-center text-indigo-600 mr-3"><i class="fas fa-calendar-check"></i></div><h3 class="text-xl font-semibold">核心临床进展</h3></div><ul class="text-gray-600 space-y-3"><li><i class="fas fa-check-circle text-green-500 mr-2"></i> <span class="font-medium">胆管癌</span>：中国注册II期试验预计2025年下半年完成，全球多区域III期试验2026年完成患者招募</li><li><i class="fas fa-check-circle text-green-500 mr-2"></i> <span class="font-medium">乳腺癌</span>：联合氟维司群治疗HR+/HER2-乳腺癌II期临床于2025年9月获NMPA默示许可</li><li><i class="fas fa-check-circle text-green-500 mr-2"></i> <span class="font-medium">肝细胞癌</span>：2025年9月4日完成与PD-1抑制剂（卡度尼利/依沃西）联合用药II期临床首例患者给药</li><li><i class="fas fa-check-circle text-green-500 mr-2"></i> <span class="font-medium">mCRPC</span>：单药及联合新型激素疗法（NHT）的II期试验推进中，2025年下半年启动联合治疗研究</li></ul></div><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-blue-100 flex items-center justify-center text-blue-600 mr-3"><i class="fas fa-project-diagram"></i></div><h3 class="text-xl font-semibold">其他管线布局</h3></div><div class="overflow-x-auto"><table class="min-w-full bg-white rounded-lg overflow-hidden"><thead class="bg-gray-100"><tr><th class="px-4 py-2 text-left">候选药物</th><th class="px-4 py-2 text-left">靶点/机制</th><th class="px-4 py-2 text-left">适应症</th><th class="px-4 py-2 text-left">临床阶段</th></tr></thead><tbody class="divide-y divide-gray-200"><tr><td class="px-4 py-2">TT-00973</td><td class="px-4 py-2">AXL/FLT3</td><td class="px-4 py-2">实体瘤</td><td class="px-4 py-2">中国临床阶段</td></tr><tr><td class="px-4 py-2">TT-01488</td><td class="px-4 py-2">可逆BTK</td><td class="px-4 py-2">CLL/MCL/WM</td><td class="px-4 py-2">美国、中国I期</td></tr><tr><td class="px-4 py-2">TT-01688</td><td class="px-4 py-2">S1P1</td><td class="px-4 py-2">UC, AD</td><td class="px-4 py-2">中国临床阶段</td></tr><tr><td class="px-4 py-2">TT-00920</td><td class="px-4 py-2">PDE9</td><td class="px-4 py-2">慢性心衰</td><td class="px-4 py-2">美国、中国I期</td></tr></tbody></table></div></div></div></section><section id="technical" class="container mx-auto py-12 px-4 md:px-8"><h2 class="text-3xl font-bold mb-12 text-center">技术面分析</h2><div class="grid grid-cols-1 md:grid-cols-2 gap-8 mb-16"><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-purple-100 flex items-center justify-center text-purple-600 mr-3"><i class="fas fa-chart-line"></i></div><h3 class="text-xl font-semibold">股价趋势与关键价位</h3></div><p class="text-gray-600 mb-4">药捷安康 - B（02617.HK）自 2025 年 6 月 23 日以 13.15 港元发行上市以来，股价呈现显著的阶段性上涨特征，可划分为上市初期震荡上行与纳入港股通后加速上涨两个核心阶段。</p><div class="chart-container"><canvas id="technicalChart"></canvas></div><div class="mt-4"><h4 class="font-semibold text-lg mb-2 text-gray-700">关键股价与市值数据</h4><div class="overflow-x-auto"><table class="min-w-full bg-white rounded-lg overflow-hidden"><thead class="bg-gray-100"><tr><th class="px-4 py-2 text-left">日期</th><th class="px-4 py-2 text-left">收盘价(港元)</th><th class="px-4 py-2 text-left">涨跌幅</th><th class="px-4 py-2 text-left">市值(亿港元)</th></tr></thead><tbody class="divide-y divide-gray-200"><tr><td class="px-4 py-2">2025-06-23</td><td class="px-4 py-2">21.65</td><td class="px-4 py-2 up-color">+64.7%</td><td class="px-4 py-2">85.9</td></tr><tr><td class="px-4 py-2">2025-08-05</td><td class="px-4 py-2">43.46</td><td class="px-4 py-2 up-color">+100.7%</td><td class="px-4 py-2">172.41</td></tr><tr><td class="px-4 py-2">2025-09-08</td><td class="px-4 py-2">91.8</td><td class="px-4 py-2 up-color">+29.5%</td><td class="px-4 py-2">365</td></tr><tr><td class="px-4 py-2">2025-09-12</td><td class="px-4 py-2">192.5</td><td class="px-4 py-2 up-color">+77.1%</td><td class="px-4 py-2">764</td></tr></tbody></table></div></div></div><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-green-100 flex items-center justify-center text-green-600 mr-3"><i class="fas fa-chart-bar"></i></div><h3 class="text-xl font-semibold">技术指标信号</h3></div><p class="text-gray-600 mb-4">截至2025年8月1日，核心技术指标呈现分化与共振并存特征：</p><div class="grid grid-cols-2 gap-4 mb-6"><div class="bg-gray-50 p-3 rounded-lg"><p class="font-medium text-gray-700">RSI(14)</p><p class="text-xl">53.085</p><p class="text-sm text-gray-500">中性</p></div><div class="bg-gray-50 p-3 rounded-lg"><p class="font-medium text-gray-700">MACD(12,26)</p><p class="text-xl">0.59</p><p class="text-sm text-green-500">买入</p></div><div class="bg-gray-50 p-3 rounded-lg"><p class="font-medium text-gray-700">Williams %R</p><p class="text-xl">-60.714</p><p class="text-sm text-red-500">卖出</p></div><div class="bg-gray-50 p-3 rounded-lg"><p class="font-medium text-gray-700">CCI(14)</p><p class="text-xl">-54.0026</p><p class="text-sm text-red-500">卖出</p></div></div><div class="bg-blue-50 rounded-xl p-4"><h4 class="font-semibold text-lg mb-2 text-blue-800">核心结论</h4><p class="text-gray-700">RSI中性（53.085）、MACD买入（0.59）与移动平均线强力买入形成共振，短期股价趋势向好。尽管STOCH、ADX等指标发出卖出信号，但核心趋势指标（均线系统）与动量指标（MACD）的一致性更强，支撑短期上行判断。</p></div></div></div></section><section id="forecast" class="container mx-auto py-12 px-4 md:px-8"><h2 class="text-3xl font-bold mb-12 text-center">股价预测</h2><div class="grid grid-cols-1 md:grid-cols-3 gap-8 mb-16"><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-red-100 flex items-center justify-center text-red-600 mr-3"><i class="fas fa-clock"></i></div><h3 class="text-xl font-semibold">短期预测（1个月）</h3></div><p class="text-gray-600 mb-4">短期股价主要催化剂为公司乳腺癌 II 期临床首例患者入组公告。参考 2025 年 9 月 12 日类似事件驱动下的股价涨幅（当日因前期临床进展公告推动股价显著上涨），本次首例患者入组作为临床阶段的重要里程碑事件，有望进一步强化市场对管线推进进度的信心。</p><div class="bg-red-50 rounded-xl p-4"><h4 class="font-semibold text-lg mb-2 text-red-800">目标价区间</h4><p class="text-2xl font-bold up-color">220-250港元</p><p class="text-sm text-gray-600">上涨概率约70%</p></div></div><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-yellow-100 flex items-center justify-center text-yellow-600 mr-3"><i class="fas fa-calendar-week"></i></div><h3 class="text-xl font-semibold">中期预测（2-6个月）</h3></div><p class="text-gray-600 mb-4">胆管癌 II 期临床试验的主要终点指标（客观缓解率 ORR 与无进展生存期 PFS）将成为估值重构的关键分水岭。若试验数据达到预设标准（ORR ≥ 30% 且 PFS ≥ 6 个月），公司估值逻辑将从传统的临床阶段生物医药企业向商业化阶段切换。</p><div class="bg-yellow-50 rounded-xl p-4"><h4 class="font-semibold text-lg mb-2 text-yellow-800">目标价区间</h4><p class="text-2xl font-bold up-color">350-400港元</p><p class="text-sm text-gray-600">上涨概率约60%</p></div></div><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-green-100 flex items-center justify-center text-green-600 mr-3"><i class="fas fa-calendar-alt"></i></div><h3 class="text-xl font-semibold">长期预测（6-12个月）</h3></div><p class="text-gray-600 mb-4">若替恩戈替尼的新药上市申请（NDA）获得监管批准，其作为全球首个 FGFR/JAK 多靶点抑制剂的差异化定位将形成显著市场竞争力。参考同类创新药商业化路径，假设该产品峰值销售额可达 10 亿美元。</p><div class="bg-green-50 rounded-xl p-4"><h4 class="font-semibold text-lg mb-2 text-green-800">目标价区间</h4><p class="text-2xl font-bold up-color">400-500港元</p><p class="text-sm text-gray-600">上涨概率约55%</p></div></div></div></section><section id="risks" class="container mx-auto py-12 px-4 md:px-8"><h2 class="text-3xl font-bold mb-12 text-center">风险提示</h2><div class="grid grid-cols-1 md:grid-cols-2 gap-8 mb-16"><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-red-100 flex items-center justify-center text-red-600 mr-3"><i class="fas fa-flask"></i></div><h3 class="text-xl font-semibold">研发与监管风险</h3></div><p class="text-gray-600 mb-4">公司核心产品管线仍处于临床开发阶段，研发与监管环节的不确定性构成公司股价波动的主要风险来源。其中，临床试验关键节点进展与监管审批标准变化是影响估值的核心变量。</p><div class="space-y-3"><div class="flex items-start"><div class="flex-shrink-0 mt-1"><i class="fas fa-exclamation-triangle text-red-500"></i></div><div class="ml-3"><p class="text-sm font-medium text-gray-700">临床试验关键节点风险</p><p class="text-sm text-gray-500">全球多中心III期临床试验（针对胆管癌适应症）计划于2026年完成患者入组，这一节点的达成效率直接决定产品上市进程。</p></div></div><div class="flex items-start"><div class="flex-shrink-0 mt-1"><i class="fas fa-exclamation-triangle text-red-500"></i></div><div class="ml-3"><p class="text-sm font-medium text-gray-700">安全性风险</p><p class="text-sm text-gray-500">替恩戈替尼作为多靶点激酶抑制剂，其作用机制可能伴随脱靶毒性，若III期试验中出现≥3级严重不良反应（AE）发生率超过15%或出现致死性AE，监管机构可能要求暂停试验。</p></div></div></div></div><div class="glassmorphism p-8 card-hover"><div class="flex items-center mb-4"><div class="w-10 h-10 rounded-full bg-orange-100 flex items-center justify-center text-orange-600 mr-3"><i class="fas fa-chart-line"></i></div><h3 class="text-xl font-semibold">市场与股价风险</h3></div><p class="text-gray-600 mb-4">药捷安康作为一家尚处于临床阶段的Biotech企业，其股价表现与市场前景面临多重维度的风险挑战，需从竞争格局、政策环境及估值逻辑三个核心层面进行系统性评估。</p><div class="space-y-3"><div class="flex items-start"><div class="flex-shrink-0 mt-1"><i class="fas fa-exclamation-triangle text-orange-500"></i></div><div class="ml-3"><p class="text-sm font-medium text-gray-700">市场竞争格局</p><p class="text-sm text-gray-500">在核心产品替恩戈替尼所处的FGFR抑制剂领域，当前全球已有14种竞品进入临床或商业化阶段，竞争态势日趋激烈。</p></div></div><div class="flex items-start"><div class="flex-shrink-0 mt-1"><i class="fas fa-exclamation-triangle text-orange-500"></i></div><div class="ml-3"><p class="text-sm font-medium text-gray-700">估值泡沫风险</p><p class="text-sm text-gray-500">当前公司市值764亿港元对应的研发费用比高达780倍，显著偏离Biotech行业平均50倍的估值水平，估值泡沫化特征明显。</p></div></div></div></div></div></section><footer class="bg-gray-100 py-8 mt-16"><div class="container mx-auto px-4 md:px-8 text-center text-gray-600"><p class="mb-2">本文仅是个人学习研究资料，任何人不得以此作为投资依据，你必须独立自主决策你的投资，责任自担</p><p>© <a href="https://www.yanzhenjie.com" class="nav-link">严振杰</a></p><p class="mb-2"><a href="http://beian.miit.gov.cn/" class="nav-link">浙ICP备16016006号</a> <a href="http://beian.miit.gov.cn/" class="nav-link">浙公网安备 33010402003470号</a></p></div></footer><script>document.addEventListener("DOMContentLoaded",(function(){document.querySelectorAll('a[href^="#"]').forEach((e=>{e.addEventListener("click",(function(e){e.preventDefault(),document.querySelector(this.getAttribute("href")).scrollIntoView({behavior:"smooth"});const t=document.getElementById("mobileMenu");if(t.classList.contains("active")){t.classList.remove("active");const e=document.querySelector("#mobileMenuButton i");e.classList.remove("fa-times"),e.classList.add("fa-bars")}}))}));const e=document.getElementById("mobileMenuButton"),t=document.getElementById("mobileMenu");e.addEventListener("click",(function(){t.classList.toggle("active");const e=this.querySelector("i");t.classList.contains("active")?(e.classList.remove("fa-bars"),e.classList.add("fa-times")):(e.classList.remove("fa-times"),e.classList.add("fa-bars"))})),document.addEventListener("click",(function(a){if(!document.getElementById("mainNav").contains(a.target)&&t.classList.contains("active")){t.classList.remove("active");const a=e.querySelector("i");a.classList.remove("fa-times"),a.classList.add("fa-bars")}}));const a=document.getElementById("summaryChart").getContext("2d");new Chart(a,{type:"bar",data:{labels:["当前股价","短期目标价","中期目标价","长期目标价"],datasets:[{label:"股价(港元)",data:[192.5,235,375,450],backgroundColor:["rgba(99, 102, 241, 0.6)","rgba(239, 68, 68, 0.6)","rgba(234, 179, 8, 0.6)","rgba(16, 185, 129, 0.6)"],borderColor:["rgba(99, 102, 241, 1)","rgba(239, 68, 68, 1)","rgba(234, 179, 8, 1)","rgba(16, 185, 129, 1)"],borderWidth:1}]},options:{responsive:!0,maintainAspectRatio:!1,scales:{y:{beginAtZero:!0,grid:{color:"rgba(0, 0, 0, 0.05)"}},x:{grid:{display:!1}}},plugins:{legend:{display:!1},title:{display:!0,text:"药捷安康股价目标预测"}}}});const s=document.getElementById("technicalChart").getContext("2d");new Chart(s,{type:"line",data:{labels:["6月","7月","8月","9月"],datasets:[{label:"股价(港元)",data:[13.15,21.65,43.46,192.5],borderColor:"rgba(99, 102, 241, 1)",backgroundColor:"rgba(99, 102, 241, 0.1)",borderWidth:2,tension:.3,fill:!0}]},options:{responsive:!0,maintainAspectRatio:!1,scales:{y:{beginAtZero:!0,grid:{color:"rgba(0, 0, 0, 0.05)"}},x:{grid:{display:!1}}},plugins:{legend:{display:!1},title:{display:!0,text:"药捷安康股价走势(2025年)"}}}})}))</script></body></html>